Skip to main content

Nautilus Biotechnology Inc

For the period ended Dec 31, 2024. Filed Feb 27, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 27, 2025

NAUT$2.38+6.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Signatures

Pursuant to the requirements of Section 13 or 15(d) of the Exchange Act the Registrant has duly caused this Annual Report to be signed on its behalf by the undersigned, thereunto duly authorized.

NAUTILUS BIOTECHNOLOGY, INC.
By:/s/ Sujal Patel
Sujal Patel
Chief Executive Officer

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Sujal Patel and Anna Mowry, and each of them, as his or her true and lawful attorney-in-fact and agent with full power of substitution, for him or her in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact, proxy and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact, proxy and agent, or his or her substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed by the following persons in the capacities and on the dates indicated:

SignatureTitleDate
/s/ Sujal PatelChief Executive Officer, President and DirectorFebruary 27, 2025
Sujal Patel(Principal Executive Officer)
/s/ Anna MowryChief Financial OfficerFebruary 27, 2025
Anna Mowry(Principal Financial and Accounting Officer)
/s/ Michael AltmanDirectorFebruary 27, 2025
Michael Altman
/s/ Melissa EpperlyDirectorFebruary 27, 2025
Melissa Epperly
/s/ Parag MallickDirectorFebruary 27, 2025
Parag Mallick
/s/ Matthew McIlwainDirectorFebruary 27, 2025
Matthew McIlwain
/s/ Farzad NazemDirectorFebruary 27, 2025
Farzad Nazem
/s/ Vijay PandeDirectorFebruary 27, 2025
Vijay Pande
/s/ Matthew L. PosardDirectorFebruary 27, 2025
Matthew L. Posard
/s/ Karen AkinsanyaDirectorFebruary 27, 2025
Karen Akinsanya
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.